
Claims:

1. A pre-filled syringe comprising a pharmaceutical composition comprising an LPA RNA interference (RNAi) agent and a pharmaceutically acceptable excipient, wherein the LPA RNAi agent comprises:
   (i) a sense strand and an antisense strand, wherein the antisense strand comprises the sequence of SEQ ID NO: 1280, wherein the sense strand comprises a sequence that is complementary to the sequence of the antisense strand; and
   (ii) a targeting group comprising an asialoglycoprotein receptor ligand, wherein the targeting group is conjugated to the sense strand.
2. The pre-filled syringe of claim 1, wherein the targeting group is conjugated to the 5′ end of the sense strand.
3. The pre-filled syringe of claim 1 or 2, wherein the sense strand and antisense strand are each 19 to 26 nucleotides in length.
4. The pre-filled syringe of claim 3, wherein the sense strand and antisense strand are each 21 nucleotides in length.
5. The pre-filled syringe of any of claims 1-4, wherein the LPA RNAi agent comprises one or two blunt ends.
6. The pre-filled syringe of claim 5, wherein the LPA RNAi agent comprises two blunt ends.
7. The pre-filled syringe of any one of claims 1 to 6, wherein the sense strand, the antisense strand, or both the sense and antisense strand comprise one or more modified nucleotides.
8. The pre-filled syringe of claim 7, wherein the one or more modified nucleotides are independently selected from a 2'-modified nucleotide, a locked nucleotide, an abasic nucleotide, an inverted deoxynucleotide, a morpholino nucleotide, a 2',3'-seco nucleotide mimic, or a nucleotide containing a non-natural base.
9. The pre-filled syringe of claim 8, wherein the 2'-modified nucleotide is a 2'-O-methyl nucleotide, a 2'-deoxy-2'-fluoro nucleotide, a 2'-deoxynucleotide, a 2'-methoxyethyl nucleotide, a 2'-amino nucleotide, or a 2'-alkyl nucleotide.
10. The pre-filled syringe of any one of claims 1 to 9, wherein the LPA RNAi agent comprises one or more phosphorothioate internucleoside linkages.

11. The pre-filled syringe of claim 10, wherein both the sense and antisense strand independently comprise 1, 2, 3, or 4 phosphorothioate internucleoside linkages.

12. The pre-filled syringe of any one of claims 1 to 11, wherein the asialoglycoprotein receptor ligand comprises galactose, galactosamine, N-acetyl-galactosamine, or a galactose derivative.

13. The pre-filled syringe of any one of claims 1 to 11, wherein the targeting group comprises:



wherein NAG is N-Acetyl-Galactosamine and X is selected from the group consisting of O and S.

14. The pre-filled syringe of any one of claims 1 to 13, wherein the antisense strand comprises the sequence of SEQ ID NO:188 and the sense strand comprises the sequence of SEQ ID NO:384.

15. The pre-filled syringe of claim 14, wherein the antisense strand comprises the sequence of modified nucleotides according to SEQ ID NO: 790 and the sense strand comprises the sequence of modified nucleotides according to SEQ ID NO: 1189.

16. The pre-filled syringe of any one of claims 1 to 13, wherein the antisense strand comprises the sequence of SEQ ID NO:164 and the sense strand comprises the sequence of SEQ ID NO:376.

17. The pre-filled syringe of claim 16, wherein the antisense strand comprises the sequence of modified nucleotides according to SEQ ID NO: 787 and the sense strand comprises the sequence of modified nucleotides according to SEQ ID NO: 1191.

18. The pre-filled syringe of any one of claims 1 to 13, wherein the antisense strand comprises the sequence of SEQ ID NO:164 and the sense strand comprises the sequence of SEQ ID NO:357.

19. The pre-filled syringe of claim 18, wherein the antisense strand comprises the sequence of modified nucleotides according to SEQ ID NO: 709 and the sense strand comprises the sequence of modified nucleotides according to SEQ ID NO: 1135.

20. The pre-filled syringe of any one of claims 1 to 19 for use in therapy.

21. Use of the pre-filled syringe of any one of claims 1 to 19 in the manufacture of a medicament for treating coronary artery disease in a subject.

22. Use of the pre-filled syringe of any one of claims 1 to 19 in the manufacture of a medicament for treating peripheral artery disease in a subject.

23. The use of claims 21 or 22, wherein the use further comprises that an additional therapeutic selected from the group consisting of an HMG CoA reductase inhibitor, ezetimibe, a PCSK9 inhibitor, a CTEP inhibitor, an ANGPTL3-targeting therapy, an APOC3-targetng therapy, and niacin is to be administered to the subject.

24. The use of any one of claims 21 to 23, wherein the pre-filled syringe is to be used to administer the pharmaceutical composition to the subject by subcutaneous injection.